Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Retained Earnings (2020 - 2025)

Tango Therapeutics has reported Retained Earnings over the past 6 years, most recently at -$603.2 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$603.2 million for Q4 2025, down 179609.52% from a year ago — trailing twelve months through Dec 2025 was -$603.2 million (down 179609.52% YoY), and the annual figure for FY2025 was -$603.2 million, down 179609.52%.
  • Retained Earnings for Q4 2025 was -$603.2 million at Tango Therapeutics, down from $121000.0 in the prior quarter.
  • Over the last five years, Retained Earnings for TNGX hit a ceiling of $750000.0 in Q3 2024 and a floor of -$603.2 million in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$2.5 million (2022), compared with a mean of -$98.4 million.
  • Biggest five-year swings in Retained Earnings: tumbled 949135.29% in 2021 and later skyrocketed 128.14% in 2025.
  • Tango Therapeutics' Retained Earnings stood at -$161.3 million in 2021, then skyrocketed by 97.7% to -$3.7 million in 2022, then surged by 105.02% to $186000.0 in 2023, then surged by 80.65% to $336000.0 in 2024, then plummeted by 179609.52% to -$603.2 million in 2025.
  • The last three reported values for Retained Earnings were -$603.2 million (Q4 2025), $121000.0 (Q3 2025), and $94000.0 (Q2 2025) per Business Quant data.